Testing effectiveness (Phase 2)Study completedNCT03264989
What this trial is testing
Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)
Who this might be right for
Sickle Cell Disease (SCD)
Novartis Pharmaceuticals 57